The company had developed and patented an improved delivery platform for long-acting biopharmaceuticals and then used that technology to develop new therapies to treat chronic diseases. The Transceptor® technology utilized a unique biological pathway to allow efficient delivery of SynFusion™ drug therapies. Several firms licensed the technologies in combined development deals to address Hemophilia B several different conditions, autoimmune disorders, and infertility infertility, as well as for use in enhanced peptide inhalation.
The firm had used up Rounds An and B and Angel cash of venture capital funding and was looking for an added $80 - $100 million for growth. In September 2006, Syntonix was in negotiations with a VC syndicate to obtain a 'C' Round of capital. One member of the proposed syndicate, Biogen Idec, signaled interest in purchasing Syntonix. The creators needed to make a decision about the offer.
Syntonix Pharmaceuticals case study solution
PUBLICATION DATE: January 25, 2009 PRODUCT #: NA0034-HCB-ENG
This is just an excerpt. This case is about FINANCE & ACCOUNTING
Related Case Solutions & Analyses:
See No Evil: Why We Overlook Other Peoples Unethical Behaviour
Accounting for Customer Acquisition at ADT Corporation
Zenglibao: An Internet Money Market Fund Run by Tianhong Asset Management Co., Ltd.
Berendsen Island
Alfred Brooks Menswear Limited
Businesses for Sale by Briggs Capital, 2010
Greg Mazur and the Purchase of Great Eastern Premium Pet Foods
Mittel Technologies, AG
Airwide International
Innovation at the Treasury: Treasury Inflation-Protection Securities (B)
